Proteomics reveals age-linked protein changes in human oocytes, offering clues to fertility preservation

A girl diagnosed with cancer at age ten faces an impossible choice: undergo chemotherapy that will likely destroy her ovaries, or forgo treatment. If she chooses the drugs, her chance of having biological children someday depends on a procedure that, for patients her age, rarely works. Researchers at Northwestern University have begun to understand why.

Fertility preservation through ovarian tissue cryopreservation, or OTC, offers a lifeline for prepubertal patients and anyone who cannot delay cancer treatment long enough to retrieve mature eggs. The tissue is frozen and stored; years later, after treatment ends and the patient is healthy, the tissue can be thawed and the eggs matured in the laboratory. For young children facing chemotherapy or radiation, it is the only option for biological parenthood. Yet the science lags far behind the need. When oocytes from patients younger than twenty-one are matured in the lab, success rates plummet. Outside the narrow window of ages twenty-one to thirty-two, the odds of producing a viable egg drop sharply. This means the youngest patients—those with the most years ahead of them—have the worst chances of success.

The reason has remained largely mysterious. Scientists have begun mapping the molecular landscape of adult oocytes, but no one had looked closely at the proteins in eggs from children and adolescents. Without that knowledge, there was no way to understand what made young oocytes different, or how to improve the laboratory maturation process. Nickolas Fisher and his team at Northwestern, working with colleagues at Anne & Robert H. Lurie Children's Hospital of Chicago, decided to fill that gap.

They collected oocytes from donors across three age groups: prepubertal children, adolescents, and adults. Using a technique called single-cell proteoform imaging mass spectrometry, they mapped the distinct protein forms present in each egg. The method is exacting—it can detect intact proteins and their chemical modifications in individual cells, revealing details that standard approaches miss. What they found was striking: even eggs from the same donor showed tremendous variation in their protein makeup. Yet eggs from the same person were more similar to each other than to eggs from someone else, suggesting that individual biology shapes oocyte composition in measurable ways.

The researchers zeroed in on a group of proteins called the subcortical maternal complex, known to be critical for egg maturation and early embryo development. Two proteins in particular caught their attention: OOEP and KHDC3. The abundance of OOEP shifted with the donor's age—younger patients had different levels than older ones. KHDC3 told a different story. In nearly every donor, this protein carried a chemical tag called phosphorylation, a modification that alters how the protein functions. The single exception was a donor who had already received gonadotoxic therapy before the tissue was frozen, suggesting that cancer treatment itself leaves a molecular mark on the egg.

These findings map the terrain but do not yet explain the mechanism. The researchers have identified what changes across the pubertal transition; the next step is understanding whether those changes cause the maturation problems, or whether they are symptoms of something deeper. If the age-linked protein differences are indeed responsible for lower success rates, then interventions targeting those specific proteins might improve outcomes. For now, the work establishes a foundation: a detailed molecular portrait of how oocytes differ across ages, and a toolkit for investigating why those differences matter. The path from discovery to clinical improvement is long, but for young patients facing fertility-threatening treatment, even the first clear map of the problem is progress.